A phase II study of intraoperative radiotherapy using a low-energy x-ray source for resectable pancreatic cancer: a study protocol

Jun Won Kim1, Yeona Cho1, Hyung Sun Kim2, Won Hoon Choi1, Joon Seong Park2* and Ik Jae Lee1*

Abstract

Background: The current standard treatment for resectable pancreatic cancer is surgical resection followed by adjuvant chemotherapy. Local recurrence rates are high even after curative resection; thus, the long-term outcome of locally advanced pancreatic cancer remains poor. Intraoperative radiotherapy (IORT) uses a low-energy x-ray source to deliver a single fraction of high-dose radiation to the tumor bed during a surgical procedure, while effectively sparing the surrounding normal tissues. IORT has the potential to improve the efficacy of radiation therapy for pancreatic cancer.

Methods/design: This prospective, one-armed, phase II study will investigate the role of IORT in improving local control in patients with resectable pancreatic adenocarcinoma. The patients will receive surgery and IORT of 10 Gy prescribed at a 5-mm depth of the tumor bed, followed by adjuvant gemcitabine chemotherapy according to the current standard of care. The aim is to enroll 42 patients.

Discussion: The primary endpoint of this trial is to evaluate the feasibility of IORT and the local recurrence rate after one year. The secondary endpoints include the acute and late toxicities, and disease-free survival and overall survival rates.

Trial registration: The trial was prospectively registered at Clinicaltrials.gov NCT03273374 on September 6, 2017.

Keywords: Resectable pancreatic cancer, Intraoperative radiotherapy, Low-energy x-ray source, Local control

Background

Pancreatic cancer is the fourth most common cause of cancer-related mortality in the Western world [1, 2]. Although, surgical resection offers potentially curative treatment for pancreatic adenocarcinoma, only 15–20% of patients are candidates for curative pancreatectomy [3]. Even after successful surgical resection, long-term survival is rare, and the five-year survival rate of patients with resected pancreatic adenocarcinoma is approximately 10% [4]. The predominant sites of recurrences are both local and distant in the majority of patients who undergo pancreatic resection, suggesting that most patients may have occult metastatic or local/regional disease (or both) at the time of surgery. Several prospective studies have shown that combined modality approaches using adjuvant chemotherapy or chemoradiation in addition to surgery can improve locoregional control and survival [5–7].

Previous trials involving external beam radiation therapy (EBRT) have shown improved local control in combination with surgical resection [6, 8]. However, the efficacy of EBRT in pancreatic cancer is limited by the difficulty of delivering an adequate dose of radiation due to the limited tolerance of critical organs, including the stomach, small bowel, kidney, liver, and spinal cord. Furthermore, adjuvant EBRT concurrently administered with gemcitabine is excluded from reimbursement by the Korean National Health Insurance. During a surgical procedure, intraoperative radiation therapy (IORT) delivers a single fraction of high-dose radiation to the tumor bed after gross total resection, suggesting that most...
resection or remaining residual tumor. IORT has the potential to improve the efficacy of radiation therapy for pancreatic cancer by reducing radiation dose to the normal tissue and allowing the escalation of radiation dose to the tumor bed to further improve local control [9, 10]. This is important in pancreatic cancer because local failure rates are as high as 50–80% in patients with resected and locally advanced disease [11].

In a conventional IORT procedure, the patient has to be transferred from the operating theater to a shielded radiation treatment room during open laparotomy or the entire operation must be performed in a radiation treatment room which is inadequately equipped for surgical operation [12]. Intrabeam (Carl Zeiss, Germany) is a mobile IORT system equipped with a miniature x-ray source of 50 kV that allows an entire IORT procedure to be performed inside an operating theater, eliminating the need for patient transfer during high-risk operations such as pancreatectoduodenectomy [13]. The low-energy, 50 kV peak x-ray has dose attenuation characteristics that follow the inverse cubic law (1/r^3). The steep dose gradient generated by the Intrabeam system allows the delivery of high-dose radiation to the tumor bed surface while effectively limiting delivery of significant doses to the surrounding normal tissues [14]. Furthermore, the relative biologic effectiveness (RBE) of 50-kV x-rays from the Intrabeam at depths clinically relevant for tumor-bed irradiation was determined to be 1.26 to 1.42 [15], thus increasing the likelihood of successful local control in patients undergoing IORT using the 50-kV x-ray source.

**Methods/design**

**Hypothesis**

This trial tests the hypothesis that IORT in addition to the current standard of care will improve local control compared with that observed so far in patients with resectable pancreatic adenocarcinoma.

**Study objectives and endpoints**

The primary endpoint is to evaluate the local recurrence rate after one year. The secondary endpoints include disease-free survival (DFS) and overall survival (OS) rates as well as acute and late toxicities, perioperative morbidity and mortality, and quality of life.

**Study design and period**

The purpose of the study is to investigate the role of IORT in patients with primarily resectable pancreatic cancer. The trial will be conducted as a single-center, one-armed phase II study. The trial has been registered at www.clinicaltrials.gov (NCT03273374). Patients will be recruited at the Pancreatobiliary Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine. The expected total duration of patient enrollment is two years and the follow-up period is three years.

**Patient selection and enrollment criteria**

**Inclusion criteria**

- 20 years of age or older
- Histologically confirmed adenocarcinoma of the pancreas
- Eastern Cooperative Oncology Group performance status scores of 0–2
- Resectable disease defined as follows:
  - Absence of distant metastases
  - Clear fat planes around the celiac axis, hepatic artery, and superior mesenteric artery
  - Absence of direct involvement of inferior vena cava or aorta
- Stage I–III disease per the seventh edition of the American Joint Committee on Cancer
- Adequate bone marrow function (hemoglobin > 10 g/dL, absolute neutrophil count > 1500/mm^3, platelets > 100,000/mm^3)
- Adequate renal function (serum creatinine < 1.4 mg/dL, BUN < 20 mg/dL)
- Written informed consent

**Exclusion criteria**

- Prior EBRT in the abdominal area
- A tumor bed which cannot be adequately covered by the IORT field as defined by the radiation oncologist
- Neoadjuvant chemotherapy
- Unresectable disease
- Presence of distant metastases
- Pregnancy or currently nursing

**Sample size calculation**

The primary endpoint of the trial is the local recurrence rate after one year. The study is designed to demonstrate that IORT using a low-energy x-ray source delivered to the tumor bed of the resected pancreatic cancer followed by standard adjuvant chemotherapy can improve the local recurrence rate after one year. The local recurrence rate one year after resection in our institution was 36%; the local recurrence rates after one year in comparable patient populations treated with IORT and resection ranged between 21 and 41.6% [16–19]. The sample size calculation was designed on the assumption that addition of IORT will decrease the local recurrence rate after one year by 14% (from 36 to 22%) with a power of 80%. Using the two-sided binomial test with a level of significance of α = 5%, the study requires 33 patients. Assuming a drop-out rate of 20%, a total of 42 patients will be required for this trial.
**Pretreatment evaluation**

The initial workup will consist of physical examination, laboratory tests including tumor markers, computed tomography (CT) or magnetic resonance imaging (MRI) of the abdominal cavity, thoracic CT, and biopsy. Positron emission tomography (PET) will be performed, when necessary, to detect distant metastasis. Percutaneous or endoscopic biliary drainage will be recommended for patients with obstructive jaundice before or during treatment.

**Treatment**

All patients who fulfill the inclusion criteria and provide written informed consent will be assigned to the treatment regimen shown in Fig. 1. An explorative laparotomy will be performed and the indication to continue with a resection will be based upon the absence of peritoneal or distant metastasis and the loco-regional extension of the disease, particularly major vascular involvement. A curative resection either as pancreatoduodenectomy or distal pancreatectomy will be performed.

The mobile 50-kV x-ray source (Intrabeam) will be attached to the robotic arm, which maintains the stability of the source throughout the procedure (Fig. 2). The isotropy and output of the IORT unit are verified and the pre-IORT calibration process required by the system is performed prior to each treatment. The target volume of IORT includes the tumor bed, the celiac and superior mesenteric origins, the mesenteric root, and the portal vein or any areas deemed risky by the surgeon and the radiation oncologist. An applicator with an appropriate diameter (3.0, 3.5, or 4.0 cm) will be selected according to the size of the target volume, and the applicator attached over the probe of the x-ray source. A sterile sheath will be draped over the IORT device to prevent contamination, and the applicator will be placed on the tumor bed by a radiation oncologist in correspondence with the treating surgeon. Uninvolved radiosensitive tissues will be removed and shielded from the treatment area. After locking the device in a treatment position and placing additional shielding over the surgical field to protect the operators, the target volume will be irradiated with a single dose of 10 Gy, prescribed at a 5-mm depth into the tumor bed. Eight to 12 weeks following surgery or after wound healing, the patients will receive adjuvant chemotherapy with six cycles of gemcitabine every four weeks. Each chemotherapy cycle consists of three weekly gemcitabine doses.

| Resectable pancreatic cancer | Age ≥ 20 years | EGOG 0-2 | Informed consent |
|-------------------------------|---------------|----------|-----------------|
| Surgical resection            | IORT          | IORT     | Adjuvant chemotherapy |
|                               | Not feasible  | 10 Gy @ 5 mm depth | Gemcitabine 1000 mg/m² x 6 cycles |
|                               |               |          | Follow-up CT/MRI |
|                               |               |          | Every 3-6 months |

*Fig. 1 Treatment schedule*
of 1000 mg/m² administered by intravenous infusion during a 30-min period, followed by one week of rest [20].

Follow-up and assessment of efficacy
Regular follow-up visits will take place every three months after surgery for the first two years and every six months thereafter. Patients will be followed with physical examinations, tumor markers measurement, imaging studies including CT or MRI of the abdominal cavity, and PET-CT when necessary.

The local recurrence rate after one year is the primary endpoint of the trial. It will be assessed by repeated CT, MRI, or PET-CT during regular follow-up. In case of suspected local recurrence, histological confirmation will be attempted. New lesions with typical radiological signs of a local recurrence in combination with or without increase in the levels of tumor markers will be considered a local recurrence. DFS and OS are the secondary endpoints of the study. DFS will be counted from the day of surgery until the date of the first local or distant event or death due to any cause. Patients alive without recurrent disease at the time of data analysis will be censored at the time of the most recent follow-up. The OS will be determined from the day of surgery until death due to any cause. For timed endpoints including DFS and OS, the Kaplan-Meier survival analysis followed by multivariable Cox proportional hazards model for adjusting for baseline variables will be used. P-values < 0.05 will be considered significant. Patients alive or lost to follow-up will be censored at the date of the last follow-up visit. Toxicity will be assessed according to Common Terminology Criteria for Adverse Events Version 3.0. Any toxicity occurring within three months after surgery will be considered acute toxicity. Late toxicity will be assessed during the regular follow-up visits.

Safe evaluation and reporting of adverse effects
Adverse and serious adverse events must be reported in order to protect participants. Study participation will be terminated, if the patient suffers from a grade 4 toxicity related to treatment, if a different treatment is required that is not approved in this trial, or if the patient withdraws consent for further participation. Serious adverse events will be reported within seven days of detection by the investigators.

Discussion
This trial investigates whether the addition of IORT using a low-energy x-ray source to the standard treatment, consisting of surgical resection (pancreatoduodenectomy or distal pancreatectomy) followed by adjuvant chemotherapy, improves the local recurrence rate after one year. The treatment outcomes of pancreatic cancer remain poor and local failure rates are as high as 50–80% in patients with resected and locally advanced disease [11]. The physical characteristics and relative biological effectiveness of 50 kV x-ray allow high-dose irradiation of the tumor bed while effectively sparing the surrounding normal tissues [14, 15]. The mobile Intrabeam IORT system also allows a single-fraction treatment during surgery without having to transfer the patient out of the operating theater.

The treatment schedule in this study consists of pancreatectoduodenectomy or distal pancreatectomy and IORT followed by adjuvant chemotherapy of full-dose gemcitabine (1000 mg/m²). Unlike adjuvant EBRT, IORT does not require delayed administration or dose reduction of adjuvant gemcitabine due to the increased risk of radiation toxicity with concurrent administration. Furthermore, IORT allows an additional treatment option of
adjuvant EBRT for high-risk patients such as those with narrow R0 or R1 resection in the final pathology report.

IORT with a mobile low-energy x-ray source has potential to improve local control; this phase II trial will evaluate the role of IORT in patients with resectable pancreatic cancer.

Abbreviations
CT: Computed tomography; DFS: Disease-free survival; EBRT: External beam radiation therapy; IORT: Intraoperative radiotherapy; MRI: Magnetic resonance imaging; OS: Overall survival; PET: Positron emission tomography

Acknowledgements
Not applicable.

Funding
This work was supported by the Faculty Research Grant from Yonsei University College of Medicine (6–2016-0094) and the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Republic of Korea (2017R1D1A1B03035047). These funding sources approved this study; however, they had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, writing the manuscript, or decision to submit results.

Availability of data and materials
The trial is ongoing and collecting data. The clinical datasets will be available by the corresponding author.

Trial status
The trial was opened in September 2017 with one active institution. This study is currently in the recruitment phase with a target to enroll 42 patients. (https://clinicaltrials.gov/ct2/show/NCT03273374?term=inntraoperative+radiotherapy&cond=Pancreatic+Cancer&rank=5)

Authors’ contributions
JK participated in the trial designing, conducted IORT, and prepared the manuscript. YC prepared the study protocol, and conducted IORT. HK assisted in preparing the study protocol and conducted the surgical procedures. WC assisted in preparing the study protocol and conducted the medical physics procedures. JP designed the trial, conducted surgical procedures, and conducted the correspondence. IL designed the trial, prepared the study protocol, and conducted the correspondence. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study protocol was approved by the institutional review board at Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea (3–2017–0171) on June 12, 2017. The study complies with the Declaration of Helsinki and the principles of Good Clinical Practice. All patients who fulfill the inclusion criteria will provide written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 3 December 2018 Accepted: 19 February 2019
Published online: 07 March 2019

References
1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37(Suppl 8):54–66.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10–30.
3. Sener SF, Fremgen A, Menck HR. Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999;189(1):1–7.
4. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Büchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91(10):S86–94.
5. Klinkenbijl JH, Jeekel J, Sahnoud T, van Pel R, Couvreur ML, Veenhofs CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776–82 discussion 782–774.
6. Hazard L, Tward JD, Sabo A, Shrieve DC. Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the surveillance, epidemiology, and end results (SEER) registry data. Cancer. 2007;110(10):2191–201.
7. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Derenenis C, Lacaine F, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–10.
8. Kaiser MH, Eilberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120(8):899–903.
9. Kinsella TJ, Sin德尔af W. Intraoperative radiotherapy for pancreatic carcinoma. Experimental and clinical studies. Cancer. 1996;76:Suppl 598–604.
10. Palta M, Willert C, Czito B. The role of intraoperative radiation therapy in patients with pancreatic cancer. Semin Radiat Oncol. 2014;24(2):26–31.
11. Smeenk HG, Tran TC, Erdmann J, van Eijck CH, Jeekel J. Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? Langenbecks Arch Surg. 2005;390(2):94–103.
12. Shipley WU, Tepper JE, Washaw AL, Orlow EL. Intraoperative radiation therapy for patients with pancreatic carcinoma. World J Surg. 1984;8(6):299–34.
13. Guo S, Reddy CA, Kolar M, Woody N, Mahadevan A, Delbel FC, Dietz DW, Remzi FH, Suh JH. Intraoperative radiation therapy with the photon radiosurgery system in locally advanced and recurrent rectal cancer: retrospective review of the Cleveland clinic experience. Radiat Oncol. 2012;7:110.
14. Park CC, Yom SS, Podgorsak MB, Harris E, Price RA Jr, Bevan A, Pouliot J, Konski AA, Wallner PE. Electronic Brachytherapy Working G. American Society for Therapeutic Radiology and Oncology (ASTRO) emerging technology committee report on electronic brachytherapy. Int J Radiat Oncol Biol Phys. 2010;76(4):963–72.
15. Liu Q, Schneider F, Ma L, Wenz F, Herskind C. Relative biologic effectiveness (RBE) of 30 kV X-rays measured in a phantom for intraoperative tumor-bed irradiation. Int J Radiat Oncol Biol Phys. 2013;85(4):1277–32.
16. Sindelar WF, Kinsella TJ. Studies of intraoperative radiotherapy in carcinoma of the pancreas. Ann Oncol. 1999;10(Suppl 4):226–30.
17. Zerbì A, Fossati V, Parolin D, Carlucci M, Balzano G, Bordogna G, Staudacher C, Di Carlo V. Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer. Cancer. 1994;73(12):2930–5.
18. Alffrin S, Morganti AC, Di Giorgio A, Valenti V, Bossola M, Trodella L, Cellini N, Doglietto GB. Improved survival and local control after intraoperative radiation therapy and postoperative radiotherapy: a multivariate analysis of 46 patients undergoing surgery for pancreatic head cancer. Arch Surg. 2001;136(3):343–7.
19. Showalter TN, Rao AS, Rani Anne P, Rosato FE, Rosato EL, Andrel J, Hyslop T, Xue X, Berger AC. Does intraoperative radiation therapy improve local tumor control in patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma? A propensity score analysis. Ann Surg Oncol. 2009;16(8):2116–22.
20. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski J, Schramm H, Fahlke J, Zuelke C, Burkart C, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77.